

Niki Katsiki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7609493/niki-katsiki-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

238
papers

5,155
citations

36
h-index

60
g-index

290
ext. papers

6,659
ext. citations

4.1
avg, IF

6.4
L-index

#	Paper	IF	Citations
238	Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks.. <i>Journal of Stroke</i> , 2022 , 24, 163-165	5.6	
237	Omega-6 fatty acids and the risk of cardiovascular disease: insights from a systematic review and meta-analysis of randomized controlled trials and a Mendelian randomization study.. <i>Archives of Medical Science</i> , 2022 , 18, 466-479	2.9	1
236	An altered microbiota pattern precedes Type 2 diabetes mellitus development: From the CORDIOPREV study.. <i>Journal of Advanced Research</i> , 2022 , 35, 99-108	13	3
235	Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
234	Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term.. <i>Circulation Research</i> , 2022 , CIRCRESAHA121320460	15.7	5
233	Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis.. <i>Angiology</i> , 2022 , 33197221081914	2.1	0
232	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation.. <i>Metabolism: Clinical and Experimental</i> , 2022 , 132, 155211	12.7	0
231	Influence of dietary intervention on microvascular endothelial function in coronary patients and atherothrombotic risk of recurrence. <i>Scientific Reports</i> , 2021 , 11, 20301	4.9	1
230	Could Statin Therapy Be Useful in Patients With Coronavirus Disease 2019 (COVID-19)?. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 775749	5.4	3
229	Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 31, 106182	2.8	3
228	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021 , 16, 738-750	6.3	2
227	Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 690	2.1	5
226	Statin intolerance: new data and further options for treatment. <i>Current Opinion in Cardiology</i> , 2021 , 36, 487-493	2.1	5
225	Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. <i>Archives of Medical Science</i> , 2021 , 17, 739-751	2.9	0
224	Olive Oil Intake and Cardiovascular Disease Prevention: "Seek and You Shall Find". <i>Current Cardiology Reports</i> , 2021 , 23, 64	4.2	2
223	Management of Patients with Asymptomatic Carotid Stenosis May Need to Be Individualized: A Multidisciplinary Call for Action. <i>Journal of Stroke</i> , 2021 , 23, 202-212	5.6	5
222	Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1941-1951	3.3	7

221	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021 , 67, 40-52	8.5	14
220	Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 2. <i>Current Vascular Pharmacology</i> , 2021 ,	3.3	1
219	Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1. <i>Current Vascular Pharmacology</i> , 2021 ,	3.3	1
218	Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021 , 129, 699-704	2.3	4
217	Higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality- insight from a US national survey. <i>International Journal of Cardiology</i> , 2021 , 326, 189-193	3.3	3
216	Dietary habits, lipoprotein metabolism and cardiovascular disease: From individual foods to dietary patterns. <i>Critical Reviews in Food Science and Nutrition</i> , 2021 , 61, 1651-1669	11.5	10
215	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 51-58	2.6	3
214	Longer sleep duration may negatively affect renal function. <i>International Urology and Nephrology</i> , 2021 , 53, 325-332	2.3	1
213	More Good News on Statins and COVID-19. <i>American Journal of Cardiology</i> , 2021 , 138, 127-128	3	6
212	Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications. <i>Medicinal Research Reviews</i> , 2021 , 41, 275-313	14.4	19
211	Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study. <i>Clinical Drug Investigation</i> , 2021 , 41, 169-176	3.2	7
210	The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 991-1001	3.9	2
209	Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review. <i>Food and Chemical Toxicology</i> , 2021 , 148, 111974	4.7	3
208	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. <i>Clinical Rheumatology</i> , 2021 , 40, 4957-4968	3.9	3
207	Management of patients with asymptomatic carotid stenosis may need to be individualized: a multidisciplinary call for action. Republication of J Stroke 2021;23:202-212. <i>International Angiology</i> , 2021 , 40, 487-496	2.2	2
206	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021 , 17, 856-863	2.9	7
205	Diabetes Mellitus and Heart Failure. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	7
204	Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14833	2.9	2

203	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. <i>Clin Res Hepatol</i>	2.4	
202	Serum uric acid: a mediator of cardio-reno-metabolic diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 1-2 <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 46, 101842	2.5	1
201	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <i>Archives of Medical Science</i> , 2020 , 16, 485-489	2.9	54
200	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020 , 19, 114	4.4	2
199	Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. <i>Archives of Medical Science</i> , 2020 , 16, 260-272	2.9	4
198	Gut microbiota and aging-A focus on centenarians. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 165765	6.9	17
197	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. <i>Metabolism: Clinical and Experimental</i> , 2020 , 107, 154218	12.7	5
196	Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1001-1005	6.7	3
195	Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
194	Association of impaired arterial wall properties with the presence of coronary artery disease in patients with abdominal aortic aneurysms. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 187-193	2.3	2
193	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020 , 155, 104719	10.2	7
192	Excessive "orthotopic" fat accumulation: Links with cardiometabolic diseases and potential drug treatment. <i>Journal of Cellular Physiology</i> , 2020 , 235, 6321-6322	7	6
191	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , 2020 , 18, 172-181	3.3	24
190	Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2020 , 18, 38-42	3.3	7
189	Perivascular adipose tissue in cardiovascular diseases. <i>Anatolian Journal of Cardiology</i> , 2020 , 23, 58	0.8	1
188	FRI0256 ADVANCED MICROCIRCULATORY DAMAGE IS ASSOCIATED WITH INCREASED PULSE WAVE REFLECTIONS IN PATIENTS WITH SSC. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 712.1-712	2.4	
187	SAT0312 SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS: A COMPARATIVE MATCHED-COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1101.1-1101	2.4	
186	The Role of microRNAs in the Development of Type 2 Diabetes Complications. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5969-5979	3.3	1

185	Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5637-5649	3.3	4
184	Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?. <i>European Journal of Internal Medicine</i> , 2020 , 72, 15-26	3.9	8
183	Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study. <i>Journal of the American College of Nutrition</i> , 2020 , 39, 407-413	3.5	5
182	Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107723	3.2	27
181	Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. <i>Metabolites</i> , 2020 , 10,	5.6	3
180	NLRP3 Inflammasome Biomarker-Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. <i>Metabolites</i> , 2020 , 10,	5.6	10
179	Diabetes and carotid artery disease: a narrative review. <i>Annals of Translational Medicine</i> , 2020 , 8, 1280	3.2	5
178	NAFLD and Statins. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3052-3053	4	1
177	Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 841-842	2.5	0
176	Monounsaturated Fatty Acid Levels May Not Affect Cardiovascular Events: Results From a Mendelian Randomization Analysis. <i>Frontiers in Nutrition</i> , 2020 , 7, 123	6.2	6
175	A Greater Flavonoid Intake Is Associated with Lower Total and Cause-Specific Mortality: A Meta-Analysis of Cohort Studies. <i>Nutrients</i> , 2020 , 12,	6.7	6
174	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. <i>Angiology</i> , 2020 , 71, 10-16	2.1	17
173	Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism. <i>Journal of Surgical Research</i> , 2020 , 245, 22-30	2.5	3
172	Tomato and lycopene consumption is inversely associated with total and cause-specific mortality: a population-based cohort study, on behalf of the International Lipid Expert Panel (ILEP). <i>British Journal of Nutrition</i> , 2020 , 124, 1303-1310	3.6	9
171	Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. <i>Atherosclerosis</i> , 2020 , 296, 49-58	3.1	14
170	Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all. <i>Journal of Diabetes</i> , 2020 , 12, 110-118	3.8	11
169	Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107408	3.2	4
168	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States. <i>Nutrients</i> , 2019 , 11,	6.7	9

167	A response to "In response to Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways". <i>Journal of Cellular Physiology</i> , 2019 , 234, 9908-9909	7	2
166	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019 , 17, 538-540	3.3	18
165	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 465-467	3.2	6
164	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1305-1306	2.5	1
163	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, 92-100	12.7	32
162	Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. <i>Drug Discovery Today</i> , 2019 , 24, 256-262	8.8	53
161	Statin use in patients with diabetes: one drug, multiple benefits. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 839-840	2.5	2
160	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2007-2017	4	14
159	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. <i>Journal of the American College of Nutrition</i> , 2019 , 38, 633-639	3.5	7
158	Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data. <i>British Journal of Nutrition</i> , 2019 , 122, 1262-1270	3.6	8
157	Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2051-2059	3.3	23
156	Cardiovascular Risk in Psoriasis: Current State of the Art. <i>Current Vascular Pharmacology</i> , 2019 , 17, 85-91	3.3	17
155	Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?. <i>Current Vascular Pharmacology</i> , 2019 , 17, 204-208	3.3	7
154	Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. <i>Current Vascular Pharmacology</i> , 2019 , 17, 564-572	3.3	28
153	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019 , 17, 515-537	3.3	12
152	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019 , 17, 498-514	3.3	23
151	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019 , 20, 805-815	10.6	33
150	Non-traumatic and non-drug-induced rhabdomyolysis. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019 , 4, e252-e263	0.9	4

149	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. <i>Archives of Medical Science</i> , 2019 , 15, 1357-1364	2.9	16
148	The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. <i>Nutrients</i> , 2019 , 11,	6.7	49
147	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2019 , 15, 1365-1374	2.9	10
146	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 253	5.7	8
145	Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. <i>Atherosclerosis</i> , 2019 , 284, 44-49	3.1	12
144	Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?. <i>Current Vascular Pharmacology</i> , 2019 , 17, 421-424	3.3	2
143	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019 , 286, 226-233	3.2	16
142	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019 , 284, 129-135	3.1	6
141	Dietary natural products as emerging lipoprotein(a)-lowering agents. <i>Journal of Cellular Physiology</i> , 2019 , 234, 12581-12594	7	17
140	Narrative review of the effects of antidiabetic drugs on albuminuria. <i>Journal of Cellular Physiology</i> , 2019 , 234, 5786-5797	7	11
139	Metabolic syndrome: joint diagnostic criteria and links with comorbidities. <i>Hormones</i> , 2019 , 18, 107-108	3.1	
138	A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study. <i>British Journal of Nutrition</i> , 2019 , 121, 1294-1302	3.6	7
137	A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. <i>Journal of Nutritional Biochemistry</i> , 2019 , 65, 66-71	6.3	13
136	Vascular endothelial growth factor: An important molecular target of curcumin. <i>Critical Reviews in Food Science and Nutrition</i> , 2019 , 59, 299-312	11.5	35
135	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2019 , 8, e021508	3	10
134	Statin loading in cardiovascular surgery: never too early to treat. <i>Current Opinion in Cardiology</i> , 2018 , 33, 436-443	2.1	18
133	Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Drugs</i> , 2018 , 78, 453-462	12.1	36
132	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 279-286	4	21

131	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018 , 39, 19-26	5.1	12
130	The link between insulin resistance parameters and serum uric acid is mediated by adiposity. <i>Atherosclerosis</i> , 2018 , 270, 180-186	3.1	38
129	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 259-278	3.8	5
128	Contrast-induced acute kidney injury: beware of the risk after coronary angiography. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 73	2.5	2
127	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 942-948	2.3	5
126	Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 266-270	3.2	56
125	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 13-42	12.7	103
124	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018 , 272, 316-322	3.2	10
123	MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment. <i>Metabolism: Clinical and Experimental</i> , 2018 , 87, 48-55	12.7	45
122	Gene Polymorphisms in Cardiovascular Disease and Cancer. <i>Angiology</i> , 2018 , 69, 738-739	2.1	0
121	Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit?. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 982-984	3.2	12
120	Leptin, cardiovascular diseases and type 2 diabetes mellitus. <i>Acta Pharmacologica Sinica</i> , 2018 , 39, 1176-1188	11.2	
119	Statins and substantially increased ALT values at baseline. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e124443,3		
118	Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks". <i>Journal of Clinical Hypertension</i> , 2018 ,	2.3	8
117	Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. <i>Journal of Cellular Physiology</i> , 2018 , 234, 223-230	7	49
116	Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2018 , 16, 385-392	3.3	5
115	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 219-227	3.3	51
114	Oxidative Stress and Inflammation: Their Role in the Pathogenesis of Peripheral Artery Disease with or Without Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2018 , 16, 547-554	3.3	17

113	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , 2018 , 24, 3638-3646	3.3	7
112	Heart Rate and Blood Pressure: "Connecting the Dots" in Epidemiology and Pathophysiology. <i>Angiology</i> , 2018 , 69, 660-665	2.1	3
111	Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. <i>British Journal of Nutrition</i> , 2018 , 120, 1272-1278	3.6	12
110	Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1232583	3.9	48
109	The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1853-1856	4	6
108	The impact of nuts consumption on glucose/insulin homeostasis and inflammation markers mediated by adiposity factors among American adults. <i>Oncotarget</i> , 2018 , 9, 31173-31186	3.3	7
107	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018 , 17, 461-478	3.1	5
106	Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES. <i>Lipids in Health and Disease</i> , 2018 , 17, 219	4.4	8
105	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 96-118	15.1	157
104	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 17-32	12.7	152
103	Semaglutide, lipid-lowering drugs, and NAFLD. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 329-330	18.1	10
102	Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> 2016;39:1684-1692. <i>Diabetes Care</i> , 2017 , 40, e46	14.6	1
101	Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. <i>Current Opinion in Cardiology</i> , 2017 , 32, 422-429	4.2	18
100	Adiponectin, lipids and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2017 , 28, 347-354	4.4	87
99	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor- α concentrations: A systematic review and meta-analysis of controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1458-1464	3.2	18
98	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. <i>Curr Med Res Opin</i> 2017;33:797-801. <i>Current Medical Research and Opinion</i> , 2017 , 33, 2261-2262	2.5	
97	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, G681-G682	5.1	3
96	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017 , 75, 307-326	6.4	183

95	Regulation of PCSK9 by nutraceuticals. <i>Pharmacological Research</i> , 2017 , 120, 157-169	10.2	68
94	Drug therapy for ectopic fat: myth or reality?. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 71-72	2.5	1
93	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017 , 66, e6	12.7	1
92	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017 , 75, 731-767	6.4	186
91	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017 , 13, 965-1005	2.9	173
90	Homocysteine and Non-Cardiac Vascular Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 3224-3232	3.3	18
89	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. <i>Lipids in Health and Disease</i> , 2017 , 16, 254	4.4	20
88	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. <i>Current Vascular Pharmacology</i> , 2017 , 16, 70-78	3.3	3
87	Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. <i>Archives of Medical Science</i> , 2017 , 13, 53-60	2.9	20
86	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , 2017 , 31, 1836-1841	6.7	15
85	Letter: statins and cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1123-1124	6.1	
84	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1243-1260	4	30
83	Sex and Circadian Periodicity of Cardiovascular Diseases: Are Women Sufficiently Represented in Chronobiological Studies?. <i>Heart Failure Clinics</i> , 2017 , 13, 719-738	3.3	11
82	Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach. <i>Current Medical Research and Opinion</i> , 2017 , 33, 305-313	2.5	4
81	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017 , 66, e1-e2	12.7	5
80	Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. <i>Current Vascular Pharmacology</i> , 2017 , 16, 15-22	3.3	13
79	Five gene variants in nonagenarians, centenarians and average individuals. <i>Archives of Medical Science</i> , 2017 , 13, 1130-1141	2.9	5
78	Lipoprotein (a) and Cardiovascular Risk: The Show Must go on. <i>Current Medicinal Chemistry</i> , 2017 , 24, 989-1006	4.3	15

77	Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1522-1532	3.3	31
76	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. <i>Current Vascular Pharmacology</i> , 2017 , 15, 218-229	3.3	22
75	The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?. <i>Current Opinion in Lipidology</i> , 2017 , 28, 88-89	4.4	1
74	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016 , 64, 241-2	13.4	7
73	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1513-4	2.5	13
72	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016 , 23, 1175-81	6.5	29
71	Postprandial dysmetabolism: assessment and treatment. <i>Hormones</i> , 2016 , 15, 572-573	3.1	1
70	Lipids, Statins and Heart Failure: An Update. <i>Current Pharmaceutical Design</i> , 2016 , 22, 4796-4806	3.3	15
69	Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. <i>Current Vascular Pharmacology</i> , 2016 , 14, 523-533	3.3	11
68	Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2016 , 14, 432-441	3.3	34
67	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2016 , 10, 64-8	0.7	2
66	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1639-1640	2.5	1
65	Off target effects of statins shape total mortality?. <i>Journal of Drug Assessment</i> , 2016 , 5, 4-5	1.5	1
64	Statins, renal function and homocysteine. <i>Pharmacological Reports</i> , 2016 , 68, 1093	3.9	
63	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1109-23	12.7	212
62	Vitamin D deficiency and metabolic syndrome: any link with statin intolerance and adipokines dysregulation?. <i>Clinical Lipidology</i> , 2016 , 11, 23-24		
61	Smoking and Arterial Stiffness. <i>Angiology</i> , 2015 , 66, 969-70	2.1	2
60	Hyperuricaemia in cardiovascular diseases: a passive or an active player?. <i>Medical Principles and Practice</i> , 2015 , 24, 269-70	2.1	8

59	Common variants of apolipoprotein E and cholesteryl ester transport protein genes in male patients with coronary heart disease and variable body mass index. <i>Angiology</i> , 2015 , 66, 169-73	2.1	2
58	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 471-2	3.3	3
57	Contrast-Induced Nephropathy: An "All or None" Phenomenon?. <i>Angiology</i> , 2015 , 66, 508-13	2.1	81
56	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , 2015 , 238, 182-4	3.1	0
55	Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan. <i>Angiology</i> , 2015 , 66, 416-21	2.1	29
54	Health benefits of the Mediterranean Diet: an update of research over the last 5 years. <i>Angiology</i> , 2015 , 66, 304-18	2.1	94
53	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 142-5	3.2	12
52	Correlation of carotid artery disease severity and vasomotor response of cerebral blood vessels. <i>Angiology</i> , 2015 , 66, 481-7	2.1	5
51	Chronic Venous Disease and Comorbidities. <i>Angiology</i> , 2015 , 66, 539-44	2.1	13
50	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015 , 30, 416-21	2.1	26
49	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6820-34	5.6	91
48	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7860-8	5.6	97
47	Atrial fibrillation and chronic kidney disease in hypertension: a common and dangerous triad. <i>Current Vascular Pharmacology</i> , 2015 , 13, 111-20	3.3	6
46	Nicotinic Acid and new-onset diabetes. <i>Hormone and Metabolic Research</i> , 2015 , 47, 544-5	3.1	2
45	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1449-61	4	33
44	Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome. <i>Angiology</i> , 2015 , 66, 856-61	2.1	26
43	Hyperuricemia as a risk factor for cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 19-20	2.5	18
42	Angiotensinogen (AGT) M235T, AGT T174M and Angiotensin-1-Converting Enzyme (ACE) I/D Gene Polymorphisms in Essential Hypertension: Effects on Ramipril Efficacy. <i>Open Cardiovascular Medicine Journal</i> , 2015 , 9, 118-26	0.7	14

41	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 912	3.2	3
40	Diabetic foot: lipids, new and old vascular risk markers. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 913-4	3.2	0
39	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 74-82		64
38	The effects of antiepileptic drugs on vascular risk factors: a narrative review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014 , 23, 677-84	3.2	46
37	The indicator test Neuropad in the assessment of small and overall nerve fibre dysfunction in patients with type 2 diabetes: a large multicentre study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014 , 122, 195-9	2.3	18
36	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. <i>Expert Review of Cardiovascular Therapy</i> , 2014 , 12, 295-6	2.5	1
35	Postprandial lipid profile in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2014 , 30, 121	2.5	6
34	Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2014 , 30, 55	2.5	
33	Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. <i>Angiology</i> , 2014 , 65, 538-42	2.1	31
32	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014 , 29, 389-95	2.1	26
31	Renal denervation: transition from pathophysiology to clinical practice. <i>Angiology</i> , 2014 , 65, 760-8	2.1	3
30	High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?. <i>Current Medicinal Chemistry</i> , 2014 , 21, 2917-26	4.3	28
29	The role of statins in the treatment of type 2 diabetes mellitus: an update. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3665-74	3.3	31
28	Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6339-49	3.3	14
27	Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. <i>Open Cardiovascular Medicine Journal</i> , 2014 , 8, 12-7	0.7	6
26	Impact of 3 Common ABCA1 Gene Polymorphisms on Optimal vs Non-Optimal Lipid Profile in Greek Young Nurses. <i>Open Cardiovascular Medicine Journal</i> , 2014 , 8, 83-7	0.7	13
25	Metabolic syndrome in clinical practice. <i>Cardiology Journal</i> , 2014 , 21, 209	1.4	1
24	Diabetes, bilirubin and amputations: is there a link?. <i>Diabetologia</i> , 2013 , 56, 683-5	10.3	14

23	Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease?. <i>Public Health</i> , 2013 , 127, 435-41	4	43
22	Epicardial fat and vascular risk: a narrative review. <i>Current Opinion in Cardiology</i> , 2013 , 28, 458-63	2.1	53
21	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. <i>Journal of Drug Assessment</i> , 2013 , 2, 67-71	1.5	4
20	Hyperuricaemia: more than just a cause of gout?. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 397-402	1.9	58
19	The role of fibrate treatment in dyslipidemia: an overview. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3124-31	3.3	82
18	Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. <i>Nutrients</i> , 2013 , 5, 928-48	6.7	92
17	Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4904-12	3.3	47
16	Uric acid and diabetes: Is there a link?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4930-7	3.3	60
15	Ezetimibe therapy for dyslipidemia: an update. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3107-14	3.3	31
14	Role of antihypertensive drugs in arterial stiffness and central pulsatile hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , 2012 , 12, 143-56	4	35
13	Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 401-20	6.4	36
12	Stroke, obesity and gender: a review of the literature. <i>Maturitas</i> , 2011 , 69, 239-43	5	41
11	Pulmonary arterial hypertension and statins: an update. <i>Current Opinion in Cardiology</i> , 2011 , 26, 322-6	2.1	15
10	Does metabolic syndrome influence outcome following percutaneous coronary intervention?. <i>Angiology</i> , 2011 , 62, 437-9	2.1	1
9	Adipokines and vascular risk in type 2 diabetes mellitus. <i>Angiology</i> , 2011 , 62, 601-4	2.1	9
8	Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: a new kid on the block. <i>Annals of Medicine</i> , 2011 , 43, 249-58	1.5	19
7	Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. <i>Current Vascular Pharmacology</i> , 2011 , 9, 698-705	3.3	43
6	Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide levels in patients with type 2 diabetes mellitus: a pilot study. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 136-47	0.7	10

5	Are we getting to lipid targets in real life?. <i>Archives of Medical Science</i> , 2010 , 6, 639-41	2.9	14
4	Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?. <i>Atherosclerosis</i> , 2010 , 211, 9-14	3.1	41
3	Dapagliflozin: more than just another oral glucose-lowering agent?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1581-9	5.9	31
2	Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010 , 22, 466-76	2.4	30
1	The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. <i>Drugs</i> , 2009 , 69, 1417-31	12.1	22